Black Titan Corp (NASDAQ:BTTC) Short Interest Down 44.3% in June

Black Titan Corp (NASDAQ:BTTC – Get Free Report) saw a significant drop in short interest in June. As of June 15th, there was short interest totaling 2,400 shares, a drop of 44.3% from the May 31st total of 4,312 shares. Based on an average daily trading volume, of 88,396 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s stock are short sold.

Black Titan Stock Up 2.9%

Shares of NASDAQ:BTTC traded up $0.02 on Wednesday, reaching $0.76. The company had a trading volume of 8,020 shares, compared to its average volume of 745,340. Black Titan has a twelve month low of $0.68 and a twelve month high of $39.00. The company has a 50-day moving average of $1.07. The stock has a market cap of $8.21 million, a PE ratio of -0.26 and a beta of 1.20. The company has a quick ratio of 4.62, a current ratio of 4.62 and a debt-to-equity ratio of 0.06.

Get Black Titan alerts:

Black Titan (NASDAQ:BTTC – Get Free Report) last issued its quarterly earnings data on Friday, June 12th. The company reported ($0.22) EPS for the quarter. The firm had revenue of $0.59 million during the quarter.

Institutional Investors Weigh In On Black Titan

A number of large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC bought a new position in shares of Black Titan in the fourth quarter valued at approximately $26,000. HRT Financial LP bought a new stake in shares of Black Titan during the 4th quarter worth $28,000. Marex Group plc bought a new stake in shares of Black Titan during the 4th quarter worth $84,000. Finally, Armistice Capital LLC acquired a new position in Black Titan in the 4th quarter valued at $840,000.

Black Titan Company Profile

(Get Free Report)

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

Featured Articles

• Five stocks we like better than Black Titan
• Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
• Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases
• Comcast’s NBCUniversal Split Puts Broadband Back in Focus
• 3 European Stocks to Carry Investors Through the Back Half of 2026

Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.